-
Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity. Genomic Biopharma Inc. will present two abstracts on two drug programs at the 2022 American Society of Human Genetics (ASHG) Annual Meeting, the first of which is a top scoring abstract at the meeting titled:
- Abstract Title: A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA vaccine
Presentation Date/Time: Wednesday, October 26, 2022, 3:00 PM – 4:45 PM Pacific Time
- Abstract Title: Novel siRNA-based therapeutic approach for Megacystis Microcolon Intestinal Hypoperistalsis Syndrome (MMIHS)
Presentation Date/Time: Thursday, October 27, 2022, 3:00 PM – 4:45 PM Pacific Time
“Dante Genomics has delivered genomic insights and diagnoses to thousands of individuals, ending many years-long diagnostic odysseys,” said Mattia Capulli, Chief Scientific Officer of Dante Genomics. “Through the creation of Genomic Biopharma Inc. we will realize our vision to support the discovery and development of personalized medicine, so that no one is diagnosed with a disease for which there is no treatment.”
Genomic Biopharma Inc. was created as a fully integrated drug discovery and development company, with a pipeline of drug programs for treatments and therapies focused on infectious and rare diseases. The Company develops its pipeline based on findings from Dante Genomics’ proprietary database of whole genomes. Genomic Biopharma’s core technology, the GBI AI, uses predictive algorithms and genomic data mining to support the identification of novel RNA-based therapeutics.
“Personalized medicine requires an integrated approach from data to clinical trials,” said Andrea Riposati, CEO of Dante Genomics. “We created Genomic Biopharma as a separate, independent company, to achieve the vision of personalized medicine and unlock the new era of genomic data based therapeutics.”
Dante Genomics provided initial funding and resources to Genomic Biopharma Inc. to kick off the new entity’s endeavors and programs. The two companies are now independent.
About Genomic Biopharma Inc.
Genomic Biopharma Inc. is a drug discovery and development company building a pipeline of drug programs focused on bringing to market treatments and therapies for infectious and rare diseases. The Company develops its pipeline based on findings from Dante Genomics’ proprietary database of whole genomes. Genomic Biopharma’s core technology, the GBI AI, uses predictive algorithms and genomic data mining to support the identification of novel RNA-based therapeutics.
Contact:
- Abstract Title: A computational approach to design a COVID-19 vaccine against a predicted SARS-CoV-2 variant: high immunogenicity, efficacy and safety of DELLERA vaccine
-
Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.
“Whole genome sequencing could be a game changer for 100x faster diagnosis for rare diseases, and we look forward to exploring a living lab opportunity in Ireland with Dante Genomics,” said Professor Martin Curley, United Nations General Assembly Symposium Chair.
The United Nations Science Summit discussed global standards to leapfrog digital health adoption by countries and healthcare systems across five continents, highlighting the need for private organizations to drive change in public healthcare systems.
“Personalized medicine needs personalized data, and the whole genome is the most personalized data available to an individual to inform better healthcare decisions,”
said Andrea Riposati, CEO of Dante Genomics.
“We are thrilled to launch Digital Health Population Genomics programs in Europe, further implementing Dante’s model to sequence your whole genome once and query it for a lifetime. Living labs allow for prompt impact on a country’s healthcare system, enabling benefits for all starting with patients.”
The first two genomic programs will launch in October 2022 with the first testing individuals for rare diseases and the second focused on prevention for healthy individuals. The data coming out of these programs will demonstrate the potential for new initiatives, offering European countries the ability to leverage Dante Genomics’ advanced platform to offer end-to-end solutions without the data and samples needing to leave the country.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Contacts:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com -
TMA Precision Health and Dante Genomics partner to help children with rare diseases through clinical whole genome sequencing solutions
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine.
“The simple act of providing a whole genome sequence is likely the single most important piece of healthcare for a patient with a rare disease, and no child or family should have to needlessly suffer because they can’t afford it,” said Joshua Resnikoff, CEO and Cofounder of TMA Precision Health. “Our mission is to bring this service to those that need it most. We are thrilled to partner with Dante Genomics to bring the highest quality genomic sequencing and interpretation services to our patients around the globe.”
Dante Genomics will provide 30X whole genome sequencing, clinical interpretation and personalized genomic reports to TMA’s patient network of more than 3.5 million people living with rare diseases for the purposes of diagnosis.
“There are so many people, especially children, suffering from undiagnosed rare diseases around the world, and it is this unmet need that we are working to serve every day,” said Andrea Riposati, CEO and co-founder of Dante Genomics. “We must work to end any diagnostic odyssey for these patients and reduce the time to diagnosis from years to days. Children with a rare disease, in any country, deserve the best clinical care, and TMA Precision Health is at the frontier to bring genomic driven care to the countries with the highest unmet need.”
Dante Genomics will utilize the genomic data related to this partnership to advance internal research related to novel target identification and drug development with the ultimate goal to go beyond diagnosis to treatment of rare disease.
TMA will incorporate the data from this partnership to continue growing the largest rare disease database in the world, with a focus on developing precision medicine solutions for rare patients everywhere.
About TMA Precision Health
TMA Precision Health is on a mission to provide personalized care and health equity for rare disease patients around the world. Our unique access to more than 3.5 million rare disease patients powers our ability to build on-demand comprehensive datasets of paired de-identified medical records and whole genomic sequencing and identify rare patients for clinical trials, giving our pharma partners a competitive edge when researching new insights and developing new treatments for this area of critically unmet need. For more information, please visit tmaprecisionhealth.com and follow us on LinkedIn.About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.Contacts:
Joshua Resnikoff
CEO of TMA Precision Health
info@tmaprecisionhealth.com
www.tmaprecisionhealth.comLaura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com -
Dante Genomics to innovate universal genomics by now offering easy, at-home blood collection kits for clinical whole genome sequencing without the use of a needle
NEW YORK, September 1, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, announced today that the Company has begun using needleless, at-home blood collection kits for its premium clinical whole genome sequencing test, thus bringing the high quality of concierge clinics to at home testing.
Dante Genomics is utilizing these at-home blood collection kits for its whole genome sequencing on the www.dantelabs.com website, making it easier than ever and virtually painless for patients to collect their blood sample on their own without having to travel to a hospital or have direct interaction with a mobile phlebotomist.
“This groundbreaking innovation comes from our relentless focus on providing universal access to the highest quality genomics technologies,” said Andrea Riposati, CEO of Dante Genomics. “Anyone, anywhere in the world, deserves to receive the most advanced genomic care. Anyone. Anywhere.”
The collection of blood samples for the use of genomics sequencing has key advantages over the collection of saliva:
- Saliva-derived DNA contains significantly less DNA than blood-derived DNA.
- There is far less risk of DNA contamination due to user error.
- Blood samples have a higher percentage of passing Quality Control standards, avoiding the need for the customer to supply an additional sample to be re-tested.
- As a result, blood collection lowers turnaround times significantly for the customer.
With this innovation, individuals anywhere in the world get access to the highest quality of genomic testing and now also the best options for sample collection.
Dante has deployed two products for blood collection:
- For the US market, an FDA registered device that collects whole liquid blood samples that are ready to be used for genomic DNA isolation and sequencing. Users can successfully collect blood samples at home without direct interaction at a lab or with a mobile phlebotomist.
- For the European market, a CE-IVD marked device delivers whole dried blood samples from the patient to the lab. Subjects can successfully collect volumetrically precise samples.
For our DNA wellness programs and other specific applications, Dante will continue to offer its saliva collection kit as an option.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com -
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites.
“This is an important milestone for the company as it expands our global footprint while providing access to those who can benefit from our cutting-edge early detection CRC test in these additional major international territories,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Dante has been an exceptional partner, and we look forward to continue working closely with them as they actively market and sell ColoAlert and also as they transition from processing samples at Mainz’s in-house facility, to their own wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) where they’ll offer localized service and support.”
Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing personalized preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals. Dante Genomics has announced that ColoAlert will be available from today on both online and offline channels.
“From our perspective, ColoAlert represents the first true step toward personalized medicine in colorectal cancer, and we are excited to leverage our expertise in genomic data to partner with Mainz in commercializing this important diagnostic tool,” said Andrea Riposati, Chief Executive Officer of Dante Genomics. “Through our partnership with Mainz, we will drive more informed healthcare decisions and empower patients with their genomic data.”
About ColoAlert
Dante Genomics announced ColoAlert. This test detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
- For more information, please visit www.mainzbiomed.com
- For media enquiries, please contact press@mainzbiomed.com
- For investor enquiries, please contact ir@mainzbiomed.com
- About Dante Genomics
About Dante Genomics
Dante Genomics annouced the availability of ColoAlert. Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at http://www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law. Today Dante Genomics announced ColoAlert in its test collection in Italy ans UAE.
Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
http://www.dantegenomics.com -
Dante Genomics to Participate in a Panel Presentation at the Canaccord Genuity 42nd Annual Growth Conference
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, and Andrea Riposati, CEO of Dante Genomics, will participate in a panel presentation on leveraging omics-based data and analytics to advance precision health to the next level on Thursday, August 11, 2022 at 9:30 AM Eastern Time.
The replay of the panel presentation will be available shortly after the conclusion of the panel discussion on the conference portal for 14 days post event.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com -
Dante Genomics partners with Emirates Post to deliver advanced genomic services in UAE
The partnership aims to enable universal access to genomic-driven wellness and longevity
June 22, 2022
Emirates Post, the official postal operator and leading express provider in the UAE, has partnered with Dante Genomics, a global leader in genomics and precision medicine, to facilitate the availability of advanced genomic services across the UAE in line with the nation’s vision of making healthcare testing accessible to everyone in the country.
The partnership follows the recent launch of Dante Genomics’ office and operations in the UAE. According to the agreement, Emirates Post will collect and drop off testing kits from Dante Labs to customers across the UAE, in addition to designating Emirates Post Customer Happiness Centers as a point of sale and drop off/collection point for the testing kits. Genetic testing provides personalized information about one’s overall wellbeing to empower them to live a healthier lifestyle.
Peter Somers, CEO of Emirates Post, said: “We are delighted that Dante Genomics entrusted us to support the expansion of their advanced genomic services across the UAE. This partnership further highlights the seamless services we provide to customers through our delivery network, which is the largest in the country. With its customer-centric and diverse choice of services, Emirates Post is an ideal delivery partner for companies looking for expansion and sustainable solutions to even the remotest parts of the country. Our exemplary services have enabled us to build trust and meet all the requirements of our customers and partners.”
Andrea Riposati, Group CEO of Dante Genomics, said that universal access to healthcare requires the universal operations that Emirates Posts has built. “Together, we can deliver advanced genomics everywhere. We are honored to partner with Emirates Post on logistics and distribution of advanced genomic services in the UAE. Emirates Post has proven a fantastic partner with a clear vision of how to democratize access to goods, services and technology for all people in the UAE,” he added.
Dante Genomics is a global leader in genome sequencing with the best technology in the healthcare industry to provide personalized preventive healthcare solutions by offering next-generation diagnostic tools direct to consumers and healthcare professionals. With the use of patented software and revolutionary technologies, including Novaseq 6000 Sequencing System and Pacbio, Dante Labs has achieved unprecedented performance in the field of genetic sequencing. Dante Labs through Novaseq 6000 Sequencing System has recorded an average Passing Filter ratio exceeding 80 per cent on each run performed, proving the lab as top performers within the industry. Passing Filter ratio measures efficiency in genomics.
-ends-
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
About Emirates Post Group
Emirates Post Group Company is a Public Joint Stock Company under Emirates Investment Authority (EIA) operating as a commercial entity across the emirates. It manages the planning of its postal operational division and subsidiaries, which consist of Emirates Post – the leading postal and express delivery provider in the region, Wall Street Exchange, Instant Cash, and the Electronic Documents Centre. The Dubai-based Company is the official entity responsible for licensing all postal, courier and logistics services within the UAE.
Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com -
GetFIT Lifestyle partners with Dante to bring the power of genomics to the world of fitness
MILAN, Italy, June 06, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, partners with GetFIT Lifestyle, the first Italian fitness group, to offer Dante’s Scientific Fitness Reports to the more than 30,000 GetFIT Lifestyle members. The goal of this partnership is to personalize an individual’s physical exercise routine based on their genetic needs rather than the traditional approach based on superficial physical characteristics or taste, ushering in a new frontier of health where genetics meets the world of fitness.
Beginning July 1, 2022, GetFIT will offer Scientific Fitness Reports within its fitness clubs to the more than 30,000 active members and all interested parties exclusively in Italy and Europe. Genetic variants are differences in DNA between people. The Dante Genomics report explains how specific genetic variants in one’s DNA can influence one’s physical aptitude and metabolism, making this an extremely useful diagnostic tool now and in the future.
The information obtained from the analysis of the genes of an individual will for the first time the ability to formulate a plan with the support of the GetFIT certified instructors to optimize a training regimen in an effective and healthy way with the goal to live a longer, healthier and more energetic life.
“We are excited to partner with GetFIT on this progressive collaboration to bring valuable genomic information to the world of fitness,” said Andrea Riposati, CEO of Dante Genomics. “At Dante, we often say ‘personalized medicine needs personalized data,’ and I am confident that our innovative genomic tests will mean a more personalized fitness regimen and training plan for all GetFIT customers uniquely tailored to their DNA.”
said Andrea Riposati, CEO of Dante Genomics.“For almost 40 years, the GetFIT Group has been taking care of people’s well-being. Present in Milan since 1984 with its fitness centers with swimming pools and thermarium and over 30,000 active members, our Mission is to inspire people to choose and maintain a healthy and active lifestyle and to feel good about themselves, through paths suitable for everyone and designed on the needs of each one,”
said Livio Leardi, GetFIT Founder.“Being able to participate as a partner of Dante in this innovative project will give our team the opportunity to create even more effective and personalized training programs, based on the characteristics of the individual person. This makes us proud to say that we have taken another step towards our goal: to highlight the importance of the symbiotic relationship between health and physical activity.”
Both companies presented the project at a press conference held at RiminiWellness last week.
About GetFIT Lifestyle
GetFIT is the first Italian fitness group with clubs in the city of Milan, Italy with over 30,000 active members. Through multifunctional, spacious and bright spaces, fitness rooms and swimming pools that coexist with thermarium and relaxation areas, GetFIT clubs are the ideal place to find fun, energy and relaxation. We select and train with passion all our team that represents with great professionalism our care for the reception and health of the body. We offer cutting-edge activities and design personalized paths to accompany our members towards the achievement of their goals. We have always chosen leading partners in the sector to take care of the well-being of the Milanese.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Contact:
Laura D’Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
http://www.dantegenomics.com -
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases.
Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization.
“Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development,” said Andrea Riposati, CEO of Dante Genomics. “When we founded Dante Genomics, we felt we had a responsibility to deliver personalized medicine beyond diagnosis so that no patient would be facing a diagnosis with no effective treatments. It is this holistic approach that challenges and motivates us as a company to accelerate science to save more lives.”
Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre-clinical phase. The newest addition to Dante’s discovery program pipeline is an mRNA oncology therapeutic in the molecular discovery phase meant to strengthen the immune system against certain cancer types. In co-development with US biotechnology company Protelica, Dante has therapies in respiratory disease and ovarian cancer, both in the non-regulatory pre-clinical phase.
Dante’s mRNA COVID vaccine program development began in early 2021 and has recently completed the regulatory pre-clinical phase and is ready for its first in-human.
“My academic background has taught me the value of RNA therapeutics, and Dante’s internal R&D leverages mRNA and siRNA technology to accelerate time to patients from concept to clinic,” said Mattia Capulli, Chief Scientific Officer of Dante Genomics. “The data and advanced timeline of our mRNA vaccine program demonstrates Dante’s high quality RNA platform and the reproducibility of this model applied to other clinical therapies.
The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The company name, Dante Genomics, comes from the compound of humanity and science. “Dante” refers to the Italian humanitarian poet and “Genomics” refers to the powerful science that takes place in a genomics lab. Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions. The Company’s holistic approach to medicine spans from sequencing and variant interpretation to discovery drug development.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Contact:
Laura D’Angelo
VP of Investor Relations
+39 0862 191 0671
-
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
- Dante Labs is a Global Leader in Genomics and Precision Medicine
- Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer
BERKELEY, Calif. and MAINZ, Germany and New York, MAY 19, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC).
Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab’s business model is managing state-of-the-art genomic sequencing laboratories in multiple international regions, and operating a robust e-commerce platform.
“As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it’s an absolute pleasure to partner with an industry leader such as Dante Labs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Our differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like-minded companies such as Dante Labs, who share our passion for forward-thinking diagnostic test development and marketing strategies.”
The partnership will first launch ColoAlert in Italy and UAE using Dante’s various established commercial channels. Samples will initially be processed at Mainz’s in-house facility and then Dante will purchase Mainz’s CE-IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante’s wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.
“We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets,” commented Andrea Riposati, Chief Executive Officer of Dante Labs. “Both the product and the Company mirror our mission to develop and market top-tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine.”
ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test’s initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.
About ColoAlert
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
For more information please visit www.mainzbiomed.com
For media enquiries, please contact press@mainzbiomed.com
For investor enquiries, please contact ir@mainzbiomed.com
About Dante Labs
Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Contact:
Laura D’Angelo
VP of Investor Relations
+39 0862 191 0671
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.